Advertisement

SYNTAX Score and Outcomes of Coronary Revascularization in Diabetic Patients

  • Amartya Kundu
  • Partha Sardar
  • Kevin O’Day
  • Saurav Chatterjee
  • Theophilus Owan
  • J. Dawn Abbott
Ischemic Heart Disease (D Mukherjee, Section Editor)
  • 141 Downloads
Part of the following topical collections:
  1. Topical Collection on Ischemic Heart Disease

Abstract

Purpose of Review

This review describes the dynamic relationship between diabetes mellitus (DM) and coronary artery disease (CAD) with respect to different revascularization strategies and how angiographic tools such as the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) score can supplement clinical decision-making.

Recent Findings

The SYNTAX score characterizes the anatomical extent of CAD in terms of the number of lesions, functional importance, and complexity. Studies not limited to patients with DM suggest that percutaneous coronary intervention (PCI) is a reasonable alternative to coronary artery bypass grafting (CABG) in patients with low-medium SYNTAX scores, while patients with high SYNTAX scores should be revascularized with CABG if operable. Similar findings were also observed for diabetes patients with multivessel disease in retrospective pooled analysis. The SYNTAX II score combines anatomical and clinical risk to improve upon the decision regarding the optimal revascularization strategy. The SYNTAX II score can be applied to patients with DM.

Summary

The SYNTAX scores provide guidance to clinicians faced with determining the optimal revascularization strategy in patients with DM and advanced CAD. Using a heart team approach, the information can be considered along with other factors that influence PCI or CABG risk.

Keywords

Diabetes PCI CABG SYNTAX 

Notes

Compliance with Ethical Standards

Conflict of Interest

Amartya Kundu, Partha Sardar, Kevin O’Day, Saurav Chatterjee, and Theophilus Owan declare that they have no conflict of interest.

Dr. J. Dawn Abbott reports clinical trial consulting for Pfizer (antihyperlipidemic therapy) and Recor (renal denervation).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Roth GA, Huffman MD, Moran AE, Feigin V, Mensah GA, Naghavi M, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015;132(17):1667–78.CrossRefPubMedGoogle Scholar
  2. 2.
    Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246–58.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Center for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the US 2011. Washington, DC: US Department of Health and Human Services.Google Scholar
  4. 4.
    Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol. 2000;36:355–65.CrossRefPubMedGoogle Scholar
  5. 5.
    Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA. 2005;293:1501–8.CrossRefPubMedGoogle Scholar
  6. 6.
    The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N. Engl. J Med. 1996;335:217–25.CrossRefGoogle Scholar
  7. 7.
    Aronson D, Edelman ER. Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord. 2010;11:75–86.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Serruys PW, Onuma Y, Garg S, Sarno G, van den Brand M, Kappetein AP, et al. Assessment of the SYNTAX score in the Syntax study. EuroIntervention. 2009;5:50–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Morice MC, Serruys PW, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121:2645–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1:219–27.PubMedGoogle Scholar
  12. 12.
    Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.CrossRefPubMedGoogle Scholar
  13. 13.
    GN L, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574–651.CrossRefGoogle Scholar
  14. 14.
    Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e652–735.CrossRefPubMedGoogle Scholar
  15. 15.
    Armstrong EJ, Rutledge JC, Rogers JH. Coronary artery revascularization in patients with diabetes mellitus. Circulation. 2013;128(15):1675–85.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013;381:639–50.CrossRefPubMedGoogle Scholar
  17. 17.
    The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation. 1997;96(6):1761–9.CrossRefGoogle Scholar
  18. 18.
    Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, et al. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol. 2006;97(12A):9G–19G.CrossRefPubMedGoogle Scholar
  19. 19.
    BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.CrossRefGoogle Scholar
  20. 20.
    Kim LJ, King SB 3rd, Kent K, Brooks MM, Kip KE, Abbott JD, et al. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (bypass angioplasty revascularization investigation in type 2 diabetes) trial. JACC Cardiovasc Interv. 2009;2(5):384–92.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010;55(5):432–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Kern M. What is the SYNTAX score and how should we use it? Cath Lab Digest. 2009;17:(8). Google Scholar
  23. 23.
    • Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardio-thoracic Surg. 2013;43(5):1006–13. Valuable 5-year follow-up of the landmark SYNTAX trial in diabetic patients. CrossRefGoogle Scholar
  24. 24.
    •• Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375–84. This is the first and largest randomized trial with diabetic patients and multivessel disease assigned to different revascularization strategies. CrossRefPubMedGoogle Scholar
  25. 25.
    Birim O, van Gameren M, Bogers AJ, Serruys PW, Mohr FW, Kappetein AP. Complexity of coronary vasculature predicts outcome of surgery for left main disease. Ann Thorac Surg. 2009;87:1097–104.CrossRefPubMedGoogle Scholar
  26. 26.
    Lemesle G, Bonello L, de Labriolle A, Steinberg DH, Roy P, Pinto Slottow TL, et al. Prognostic value of the Syntax score in patients undergoing coronary artery bypass grafting for three-vessel coronary artery disease. Catheter Cardiovasc Interv. 2009;73:612–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Mohr FW, Rastan AJ, Serruys PW, Kappetein AP, Holmes DR, Pomar JL, et al. Complex coronary anatomy in coronary artery bypass graft surgery: impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years. J Thorac Cardiovasc Surg. 2011;141(1):130–40.CrossRefPubMedGoogle Scholar
  28. 28.
    •• Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, et al. SYNTAX score and long-term outcomes: the BARI-2D trial. J Am Coll Cardiol. 2017;69(4):395–403. This study investigated associations between SYNTAX scores and revascularization outcomes in the BARI 2D trial. CrossRefPubMedGoogle Scholar
  29. 29.
    Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.CrossRefPubMedGoogle Scholar
  30. 30.
    Stone GW, Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med. 2016;375(23):2223–35.CrossRefPubMedGoogle Scholar
  31. 31.
    Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med. 2011;364:1718–27.CrossRefPubMedGoogle Scholar
  32. 32.
    Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, et al. Investigators BT. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015;372:1204–12.CrossRefPubMedGoogle Scholar
  33. 33.
    Cavalcante R, Sotomi Y, Mancone M, Whan Lee C, Ahn JM, Onuma Y, et al. Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. Eur Heart J. 2017;38:1969–77.CrossRefPubMedGoogle Scholar
  34. 34.
    Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;64:1929–49.CrossRefPubMedGoogle Scholar
  35. 35.
    Mäkikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2016;  https://doi.org/10.1016/S0140-6736(16)32052-9.
  36. 36.
    Sardar P, Giri J, Elmariah S, Chatterjee S, Kolte D, Kundu A, et al. Meta-analysis of drug-eluting stents versus coronary artery bypass grafting in unprotected left main coronary narrowing. Am J Cardiol. 2017;119(11):1746–52.CrossRefPubMedGoogle Scholar
  37. 37.
    Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/ STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Circulation. 2009;119:1330–52.CrossRefPubMedGoogle Scholar
  38. 38.
    Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JAACCF. SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2012;59(9):857–81.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Amartya Kundu
    • 1
  • Partha Sardar
    • 2
  • Kevin O’Day
    • 3
  • Saurav Chatterjee
    • 4
  • Theophilus Owan
    • 2
  • J. Dawn Abbott
    • 5
  1. 1.Department of Cardiovascular MedicineUniversity of Massachusetts Medical SchoolWorcesterUSA
  2. 2.Division of Cardiovascular MedicineUniversity of Utah Health Science CenterSalt Lake CityUSA
  3. 3.Department of MedicineUniversity of Massachusetts Medical SchoolWorcesterUSA
  4. 4.Department of Cardiology, Saint Francis Hospital, Teaching AffiliateUniversity of Connecticut School of MedicineHartfordUSA
  5. 5.Division of Cardiology, Brown Medical SchoolRhode Island HospitalProvidenceUSA

Personalised recommendations